NCT05274945View on ClinicalTrials.gov

Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions

Rectal Cancer

Interventions

RADIATION

Radiotherapy

radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil

DRUG

consolidation chemotherapy

6 cycles of FOLFOX or CAPOX

PROCEDURE

TME or APR

total mesorectal excision or abdominoperineal resection

Trial Locations (1)

Unknown

Ahmed Samir Ashoor, Alexandria

All Listed Sponsors

lead

Alexandria University

OTHER

NCT05274945 - Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter